

DOCKET NO.: 1733.2025 US2 (004)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Henry R. Costantino, Joyce M. Hotz and Edward W. Bobka

Application No.: 10/688,059

Group Art Unit: 1615

Filed:

Title:

Sir:

October 17, 2003

Examiner: Not Assigned

Confirmation No.: 8156

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

(Filed after payment of issue fee)

John Marion No., 6130

 ${\bf MICROENCAPSULATION\ and\ SUSTAINED\ Release\ of\ Biologically\ Active\ Polypeptides}$

INFORMATION DISCLOSURE STATEMENT

This In	under	on Disclosure Statement is submitted: 37 CFR 1.129(a), or cond submission after Final Rejection)
[X]	(Within a	37 CFR 1.97(b), or my one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national sta mational application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, for Continued Examination).
[]	under	37 CFR 1.97(c) together with either:
	[]	a Statement under 37 CFR 1.97(e), as checked below, or
	[]	a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under	37 CFR 1.97(d) together with:
	[]	a Statement under 37 CFR 1.97(e), as checked below, and
	[·]	a \$180.00 fee under $37\ CFR\ 1.17(p)$, or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[]		37 CFR 1.97(i): cant requests that the IDS and cited reference(s) be placed in the application filewrapper.

Statement Under 37 CFR 1.97(e)

[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or		
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.		
Statem	ent Und	er 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000	
[]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.		
[X]	Enclosed herewith is form PTO-1449:		
	[X] Copies of the cited references (AR and AS) are enclosed.		
	[] Copies of cited references are enclosed except those entered in prior application, U.S. Application, No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application controlled to the cited references.]		
[] The listed references were cited in the enclosed International Search Report in a counterp foreign application.		The listed references were cited in the enclosed International Search Report in a counterpart foreign application.	
[] The "concise explanation" requirement (non-English references) for reference(s) [CFR 1.98(a)(3) is satisfied by:			
		the explanation provided on the attached sheet. the explanation provided in the Specification. submission of the enclosed International Search Report. submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.	

-2-

The Examiner is requested to return a copy of the list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 502807 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 502807.

Respectfully submitted,

ELMORE CRAIG, P.C.

Anne T. Craig

Registration No.: 32,976 Telephone: (978) 251-3509 Facsimile: (978) 251-3973

Dated: 6/24/04

TA TRADEMAS

O 1 P E IN AN APPLICATION

use several sheets if necessary)

ATTORNEY DOCKET NO. 1733.2025 US2 (004)

APPLICANTS

FILING DATE

October 17, 2003

APPLICATION NO. 10/688,059

8156

June 22, 2004

Henry R. Costantino, et al.

CONFIRMATION NO. GROUP 1615

U.S. PATENT DOCUMENTS EXAM-INER REF. ISSUE DATE / NI-NO TIAL DOCUMENT NUMBER PUBLICATION DATE NAME Claeys et al. 3,523,906 11 Aug 1970 AA 3,691,090 12 Sept 1972 Kitajima et al. AB 05 June 1973 3,737,337 Schnoring et al. AC 24 June 1975 3,891,570 Fukushima et al. AD Morishita et al. 01 June 1976 ΑE 3,960,757 4,389,330 21 June 1983 AF Tice et al. 5,019,400 28 May 1994 Gombotz et al. ΑE 5,424,286 13 June 1995 Eng ΑH 5,656,297 12 Aug 1997 Bernstein et al. AA2 Hebert et al. 5,922,253 13 June 1999 AB2 AC2 AD2 AE2 AF2 AG2 AH2 AA3 AF3 AC3 AD3 AE3 AF3 AG3

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MMCG/

EXAMINER	DATE CONSIDERED
/Marcela M Cordero Garcia/	09/12/2008

ı	PTO-1449 REPRODUCED			
1	O PINFORMATION DISCLOSURE CITATION			
1	/ IN AN APPLICATION			
ı	/ uu 2 9 2004 61			

June 22, 2004
(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
1733.2025 US2 (004)	10/688,059

APPLICANTS
Henry R. Costantino, et al.

FILING DATE CONFIRMATION NO. 8156

. GROUP 1615

XAM- NER NI- TAL	REF.			
	NO.	APPLICATION SERIAL NUMBER	FILINGDATE	NAME
	ΑI	10/688,786	17 Oct 2003	Costantino, et al.
	ΑΙ			
	ΑΙ			
	AJ2			
	AJ2			
	AK2			
	AI3			
	AI3			
	AK3			
	AJ4			
	AJ4			
	AK4		<u> </u>	
	A15			
	Al5		-	
	AK5			
	AJ6			
	AJ6			
	AK6			
	AI7			
	AJ2			
	AK2 AI8			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MMCG/

EXAMINER	DATE CONSIDERED
/Marcela M Cordero Garcia/	09/12/2008

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	AR	Creighton, Thomas E., <u>In</u> "Proteins: Structures and Molecular Principles," Published by W.H. Freeman and Company, NY) pp. 149-150.		
	AS	Lucke, et al. "Peptide Acylation by Poly(a-Hydroxy Esters), Pharmaceutical Research, 19(2):175-181 (2002).		
	AT :			
	AU			
	ΑV			
	ΑV			
	AX			
	AY			
	AZ			
	AR2			
	AS2			
	AT2			
	AU2			
	AV2			
	AW2			
	AX2			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MMCG/

EXAMINER /Marcela M Cordero Garcia/	DATE CONSIDERED	09/12/2008